Control Bionics Limited
CBL
Rank in Stocks
#26772
Operating in Australia and North America, Control Bionics Limited and its... Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
Share Price
$0.03391731
Last synced: 2026-11-10
Market Cap
$18.46M
Change (1 day)
-2.00%
Change (1 year)
-29.76%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Control Bionics Limited (CBL)
Category
Healthcare
Operating Margin for Control Bionics Limited (CBL)
Operating Margin as of November 2026 TTM: -152.96%
According to Control Bionics Limited's latest financial reports, its current operating margin (TTM) is -152.96%. At the end of 2025 the company had an operating margin of -94.87%.
Operating Margin history for Control Bionics Limited from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -152.96% | 61.23% |
| 2025 | -94.87% | -14.38% |
| 2024 | -110.81% | 20.09% |
| 2023 | -92.27% | -30.93% |
| 2022 | -133.58% | 85.12% |
| 2021 | -72.16% | 85.74% |
| 2020 | -38.85% | -85.20% |
| 2019 | -262.48% | 99.76% |
| 2018 | -131.40% | -845.32% |
| 2016 | 17.63% | -21.57% |
| 2015 | 22.48% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.10% |
US
|
|
| 18.08% | -100.12% |
IE
|
|
| 21.25% | -100.14% |
US
|
|
| 21.05% | -100.14% |
US
|
|
| 28.09% | -100.18% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Control Bionics Limited's operating margin
What is Control Bionics Limited's operating margin?
Control Bionics Limited's operating margin is -152.96%, as of Nov 2026.
What was Control Bionics Limited's operating margin in 2025?
In 2025, Control Bionics Limited's operating margin was -94.87%, compared with -110.81% in 2024.
How has Control Bionics Limited's operating margin changed since 2020?
From 2020 to 2025, Control Bionics Limited's operating margin was highest in 2020 (-38.85%) and lowest in 2022 (-133.58%).
How does Control Bionics Limited's operating margin compare with similar companies?
Control Bionics Limited's operating margin (-152.96%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.